Milrinone

Generic Name: Milrinone

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₉N_₃O

CAS Number: 78415-72-2

Unique Ingredient Identifier: JU9YAX04C7

Background: Heart failure is a multifactorial condition that affects roughly 1-2% of the adult population. Often the result of long-term myocardial ischemia, cardiomyopathy, or other cardiac insults, heart failure results from an inability of the heart to perfuse peripheral tissues with sufficient oxygen and metabolites, resulting in complex systemic pathologies. Heart ...

Indication: Milrinone is indicated for the short-term (48 hours or less) treatment of patients with acute decompensated heart failure. Milrinone administration should occur together with close monitoring using appropriate electrocardiographic equipment and should occur in a facility equipped for the immediate treatment of potential cardiac events, including ventricular ...

Associated Conditions: Acute Decompensated Heart Failure (ADHF), Congestive Heart Failure (CHF)

Associated Therapies: -

Clinical Trials

Efficacy of Milrinone With Sildenafil in Persistent Pulmonary Hypertension in Children

Not Applicable

Completed

Conditions: Persistent Pulmonary Hypertension of the Newborn

Interventions: Drug: Sildenafil
Drug: Milrinone

First Posted Date: 2024-08-20

Last Posted Date: 2024-08-26

Lead Sponsor: Muhammad Aamir Latif

Target Recruit Count: 42

Registration Number: NCT06562036

Locations: 🇵🇰
Children's Hospital and institute of Child Health, Multan, Punjab, Pakistan

Milrinone on Right Ventricular Strain in Cardiac Surgery

Recruiting

Conditions: Ischemic Heart Disease
Valvular Heart Disease

First Posted Date: 2023-10-11

Last Posted Date: 2024-01-19

Lead Sponsor: Konkuk University Medical Center

Target Recruit Count: 41

Registration Number: NCT06077721

Locations: 🇰🇷
Konkuk University Medical Center, Seoul, Korea, Republic of

CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

Phase 4

Recruiting

Conditions: Shock, Cardiogenic

Interventions: Drug: Normal Saline
Drug: Dobutamine
Drug: Milrinone

First Posted Date: 2022-03-04

Last Posted Date: 2024-04-08

Lead Sponsor: Ottawa Heart Institute Research Corporation

Target Recruit Count: 346

Registration Number: NCT05267886

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada
🇨🇦
Hamilton Health Sciences, Hamilton, Ontario, Canada

Effect of Nebulized Milrinone on Right Ventricular Hemodynamics in Adult Cardiac Surgery

Phase 4

Conditions: Anesthesia

Interventions: Drug: Milrinone
Drug: Normal saline

First Posted Date: 2021-11-24

Last Posted Date: 2022-07-20

Lead Sponsor: Ain Shams University

Target Recruit Count: 70

Registration Number: NCT05132153

Locations: 🇪🇬
Samar Soliman, Cairo, Nasr City, Egypt

Milrinone Versus Placebo in Patients With Septic Shock

Phase 2

Recruiting

Conditions: Septic Shock
Cardiac Output

Interventions: Drug: Milrinone

First Posted Date: 2021-11-17

Last Posted Date: 2022-09-15

Lead Sponsor: Mahidol University

Target Recruit Count: 64

Registration Number: NCT05122884

Locations: 🇹🇭
Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
🇹🇭
Hat Yai Hospital, Hat Yai, Songkhla, Thailand

Efficacy and Safety of Milrinone Versus Sildenafil in the Treatment of Neonates With Persistent Pulmonary Hypertension

Phase 1

Completed

Conditions: Persistent Pulmonary Hypertension

Interventions: Drug: Milrinone
Drug: Sildenafil

First Posted Date: 2020-05-18

Last Posted Date: 2020-05-18

Lead Sponsor: Rania Ali El-Farrash

Target Recruit Count: 40

Registration Number: NCT04391478

Levosimendan Versus Milrinone in Off Pump CABG Surgery

Phase 4

Conditions: Hemodynamics

Interventions: Drug: Levosimendan
Drug: Milrinone

First Posted Date: 2019-02-27

Last Posted Date: 2019-03-07

Lead Sponsor: Assiut University

Target Recruit Count: 60

Registration Number: NCT03855579

Locations: 🇪🇬
Assiut University, Assiut, Egypt

Prophylactic Use of Milrinone After Congenital Heart Surgery in Infants

Phase 3

Conditions: Infant
Low Cardiac Output Syndrome
Cardiac Surgical Procedures

Interventions: Drug: Normal saline
Drug: Milrinone

First Posted Date: 2019-01-30

Last Posted Date: 2019-01-30

Lead Sponsor: Shanghai Children's Medical Center

Target Recruit Count: 520

Registration Number: NCT03823781

Locations: 🇨🇳
Shanghai Shanghai Children's Medical Center, Shanghai, Shanghai, China

Milrinone Versus Dobutamine in Critically Ill Patients

Phase 4

Completed

Conditions: Acute Coronary Syndrome
Low Cardiac Output Syndrome
Cardiogenic Shock
Pulmonary Edema

Interventions: Drug: Milrinone
Drug: Dobutamine

First Posted Date: 2017-07-02

Last Posted Date: 2020-06-30

Lead Sponsor: Ottawa Heart Institute Research Corporation

Target Recruit Count: 192

Registration Number: NCT03207165

Locations: 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada

Milrinone in Congenital Diaphragmatic Hernia

Phase 2

Active, not recruiting

Conditions: Congenital Diaphragmatic Hernia
Pulmonary Hypoplasia
Hypoxemic Respiratory Failure
Persistent Pulmonary Hypertension of the Newborn

Interventions: Drug: Placebo (5% Dextrose)
Drug: Milrinone

First Posted Date: 2016-11-01

Last Posted Date: 2024-11-04

Lead Sponsor: NICHD Neonatal Research Network

Target Recruit Count: 66

Registration Number: NCT02951130

Locations: 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸
Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 16 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy